NewsRelease
PatentCites HemogloBind™ in Complement Mediation
MONMOUTHJUNCTION, NJ, January11, 2017 -- Biotech Support Group reports on a recent patentreporting the simplicity and efficiency of their hemoglobin depletiontechnology for removing interferences from a Bilirubin assay in anexample describing complement-mediated diseases. The patent is:
Krishna,Neel K., and Kenji Cunnion. "Derivative Peptide Compounds andMethods of Use." U.S. Patent No. 20,160,376,322. 29 Dec. 2016.
Theinvention describes synthetic peptide compounds and uses for therapyand diagnostics of complement-mediated diseases, such as inflammatorydiseases, autoimmune diseases, and microbial infections; andnon-complement-mediated diseases, such cystic fibrosis and variousacute diseases. Thepatent states “Dueto large amounts of hemolysis in the latter time points and theassociated optical interference in bilirubin analysis, all thesamples were pre-treated with HemogloBind™ (Biotech, N.J.)prior to analysis with the Bilirubin Assay Kit”.
“Hereis another example of how removing hemoglobin can significantlyimprove the detection of bilirubin and other blood analytes.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866, [email protected]